KKL 顾客使用本产品发表的 0 篇科研文献

SKF-83566 hydrobromide is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT₂ receptor (K_i=11 nM). SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC₅₀ of 5.7 μM. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC₂) over AC₁ and AC₅ in the isolated rabbit thoracic aorta. SKF-83566 can be used for the research of parkinson’s disease and nicotine craving alleviation.

SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA]_o) evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA]_o with 5 μM. The EC₅₀ value of this effect of SKF-83566 is 1.3 μM.
SKF-83566 inhibited [H]DA uptake with an IC₅₀ of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [H]CFT, a cocaine analog, with an IC₅₀ of 0.51 μM in [H]DA uptake and [H]CFT binding studies.
Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [H]CFT binding with an IC₅₀ of 0.77 μM in LLc-PK-rDAT cell membrane preparations.

SKF 83566 hydrobromide (oral administration; 20 µg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.